The FDA issued a statement in which it states in part: “FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an option for weight loss. This can be risky for patients, as unapproved versions do not undergo FDA’s review for safety, effectiveness and quality before they are marketed.” Novo Nordisk (NVO) markets Ozempic and Wegovy injections and Eli Lilly (LLY) markets its own injectable weight-loss drug as Zepbound. Hims & Hers (HIMS) is a compounder of the weight loss drug whose shares are often volatile around news regarding GLP-1 drugs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s Promising Position in Weight Management Market Drives Buy Rating
- Giftify reports 916% w/w increase in pharmacy retailer gift cards sold
- Eli Lilly & Co: Promising CagriSema Performance Justifies Buy Rating Despite Tolerability Concerns
- Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook
- Novo Nordisk (NVO) Sinks after Weight-Loss Drug Trial Misses Expectations
Questions or Comments about the article? Write to editor@tipranks.com